Asterias Biotherapeutics Opens Additional Clinical Site for AST-OPC1 SCiStar Study

https://globenewswire.com/news-release/2017/08/23/1091407/0/en/Asterias-Biotherapeutics-Opens-Additional-Clinical-Site-for-AST-OPC1-SCiStar-Study.html

Source: Asterias Biotherapeutics FREMONT, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Washington University School of Medicine in St. Louis, MO, has been added as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1…